Skip to main content
Top of the Page

SOHO is a global society designed specifically for clinicians, research scientists and related health care professionals who specialize in the research and treatment of patients with hematologic malignancies. SOHO’s mission is to expedite worldwide research and education through the exchange of scientific information.

Learn more »

SOHO represents physicians and other professionals from all corners of the world. SOHO is leading vital efforts to further treatments for those with hematologic malignancies. Become a SOHO Member free-of-charge. Join us and experience the benefits of membership.

Join Now

The Society of Hematologic Oncology (SOHO) holds its annual meeting during the September timeframe of each year in Houston, Texas. Note that SOHO members receive a 40% discount on registration fees. We expect approximately 2,500 hematologic oncology specialists to participate in the upcoming Tenth Annual Meeting of the Society (SOHO 2022). Click for more information and registration.

Register now
  • 6,597 members strong

Join Us Today and Become a Part of the SOHO Community

Benefits of membership include:
  • Instant connections to our SOHO Community of more than 6,000 members
  • Access to a comprehensive Resource Center that includes slides, publications, abstracts, videos & more
  • Connection to our SOHO DocMatter Community for hematologic oncology discussions and education
  • Free online access to our official journal, ‘Clinical Lymphoma Myeloma and Leukemia
  • Free online and print subscription (US members) to our news publication, 'Blood Cancers Today'
  • Significant member-only discounts on meetings and events
  • Early member-only registration and housing opportunities
  • ... and much more!

Ambassador Program

The Ambassador Program was created to increase geographical diversity and promote international understanding among hematologic oncology experts around the world. If you are interested, Contact us!

Latest News


All Sessions will remain available on the Attendee Hub until October 1, 2023. Sessions are accessed through the Home page.

High Complete Molecular Response Rates with Ponatinib Plus Blinatumomab in Ph+ ALL

A chemo-free regimen with simultaneous ponatinib and blinatumomab led to high rates of complete molecular response in patients with newly diagnosed, relapsed, or refractory Ph+ ALL

FDA Approves First Noncovalent BTK Inhibitor Pirtobrutinib for MCL

Pirtobrutinib was approved under the FDA’s Accelerated Approval pathway based on data from the phase I/II BRUIN trial

Sanam Loghavi, MD, Tells Us Why 2022 was a Major Year for MDS

Sanam Loghavi, MD, stops by The HemOnc Pulse in the latest episode to chat with host Chadi Nabhan, MD, MBA, FACP, about why 2022 was a major year for MDS.

Zilovertamab Plus Ibrutinib ‘Well-Tolerated’ in Patients with R/R MCL

A phase I/II study of zilovertamab and ibrutinib in R/R MCL showed that the combination was well-tolerated and had a similar safety profile when compared with ibrutinib alone

TRIANGLE Trial Results Support First-Line Ibrutinib Use in MCL

High-dose cytarabine-containing immunochemotherapy followed by AHSCT “failed to show superiority” over an ibrutinib-containing treatment without AHSCT in MCL

Venetoclax Plus Azacitidine Shows ‘Encouraging OS’ in R/R MDS with Prior HMA Failure

Venetoclax plus azacitidine provided “clinically meaningful benefits” in patients with R/R MDS who had failed prior treatment with an HMA.

"Very interesting and exciting to share ideas and data with other hem/onc clinicians and scientists from around the world"
–Prof. Dieter Hoelzer, founding member
Back to Top